Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors

Summary

This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.

Timeline

Start

2003-01

Primary completion

—

Completion

2005-11

Publications

• Background Giles FJ. Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther. 2002 Jun;2(3):261-6. doi: 10.1586/14737140.2.3.261.

Drugs

Indications